Introduction
============

Cervical cancer (CC) is the second most common malignant tumor among women, responsible for \~527,600 new cases and \>265,700 deaths annually.[@b1-cmar-10-3533] Despite advances in screening detection and new treatment strategies, CC is one of the leading causes of cancer death among females in many developing countries.[@b2-cmar-10-3533],[@b3-cmar-10-3533] Although most patients can be cured if diagnosed at an early stage, poor prognosis is observed with secondary metastatic cancer and tumor relapse.

Although human papillomavirus (HPV) is a prerequisite for CC, only a small number of women infected by this virus develop cancer. Thus, other risk factors should be considered as cofactors contributing to the progression of CC.[@b4-cmar-10-3533] Dysregulated genes play important roles in CC development.[@b5-cmar-10-3533] Several studies have used gene expression profiling to identify key genes between CC samples and normal cervix.[@b6-cmar-10-3533]--[@b9-cmar-10-3533] Hundreds of differentially expressed genes (DEGs) were detected. However, DEGs reported in different studies vary enormously with only some of them consistently detected. Therefore, the discovery of novel effective therapeutic targets against CC is urgently required.

A number of chemotherapeutic agents have shown activity against CC, including cisplatin,[@b10-cmar-10-3533] bevacizumab,[@b11-cmar-10-3533] carboplatin,[@b12-cmar-10-3533] paclitaxel,[@b13-cmar-10-3533] ifosfamide,[@b14-cmar-10-3533] and topotecan.[@b15-cmar-10-3533] Various combinations of these agents are recommended as therapies.[@b16-cmar-10-3533] A recent systematic literature review found that carboplatin--paclitaxel is equally effective and less toxic than cisplatin--paclitaxel as the first-line therapy for metastatic CC.[@b17-cmar-10-3533] However, patients overall survival (OS) times remains short, indicating an urgent need to discover some molecular drugs that are more efficient and selective. Based on bioinformatics approaches, several studies found small molecules as potential anticancer agents.[@b18-cmar-10-3533]--[@b20-cmar-10-3533]

In this study, we selected the following microarray datasets GSE7803 and GSE9750 from the Gene Expression Omnibus (GEO) database to identify DEGs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using the identified DEGs was investigated. A protein--protein interaction (PPI) network was constructed to elucidate the significant relationships among DEGs and to identify key genes. Furthermore, the Kaplan--Meier estimator was used on the Gene Expression Profiling Interactive Analysis (GEPIA) website. Candidate small molecules were identified for their potential use in the treatment of CC.

Materials and methods
=====================

Data collection
---------------

Two CC microarray datasets were downloaded from the GEO website (<http://www.ncbi.nlm.nih.gov/geo/>). GSE7803 microarray data contained 21 CC tissues and 10 normal cervical epithelia tissues.[@b6-cmar-10-3533] GSE9750 included 33 tumors samples and 24 healthy cervical samples.[@b7-cmar-10-3533] Both the profile datasets were based on the Affymetrix GPL96 platform (Affymetrix Human Genome U133A Array). Because Connectivity Map (CMap) strictly required all probesets obtained from the Affymetrix Human Genome U133A Array,[@b21-cmar-10-3533] we predicted the drugs for the DEGs measured only in this platform with high accuracy. GSE63514 data included 28 cancer cases and 24 normal cases[@b8-cmar-10-3533] and were chosen to validate *RRM2* mRNA expression in our analysis.

Data preprocessing and DEGs screening
-------------------------------------

The raw data were standardized and transformed into expression values using the affy package of Bioconductor (<http://www.bioconductor.org/>).[@b22-cmar-10-3533] DEGs between cancer and normal samples were selected by significance analysis using the empirical Bayes methods within limma package.[@b23-cmar-10-3533] False discovery rate (FDR) \<0.05 and \|log2 (fold change)\| \>1 were set as the cutoff criteria for the identification of DEGs. Common dysregulated probesets between GSE7803 and GSE9750 were selected for subsequent analyzes.

KEGG pathway analysis
---------------------

Pathway enrichment analysis was performed using the clusterProfiler package and a pathway with an adjusted *P*-value \<0.05 was considered significantly enriched.[@b24-cmar-10-3533] DEGs that we identified could be involved in multiple pathways, Thus, some overlap was observed among the pathways. We identified the significant pathways that shared the same DEGs and used Cytoscape (version 3.5.1) to construct graphical representations of the interactive relationships among the pathways.[@b25-cmar-10-3533]

PPI network construction and analysis
-------------------------------------

The PPI pairs of the screened DEGs were analyzed using the online database STRING version 10.5 (<https://string-db.org/>).[@b26-cmar-10-3533] The pairs with combined scores \>0.4 were used for the PPI network construction, then the Cytoscape software was used to construct the network and analyze the interaction relationship of the candidate DEGs encoding proteins in CC.

Validation of key genes
-----------------------

Key genes were identified as the intersecting genes of the enrichment pathways and top 20 nodes in PPI network. To confirm the reliability of these genes from our detection, we analyzed their prognostic and expression in CC using GEPIA.[@b27-cmar-10-3533] GEPIA is an interactive web application for gene expression analysis based on 9,736 tumors and 8,587 normal samples from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression databases.[@b28-cmar-10-3533],[@b29-cmar-10-3533] We evaluated the expression of key genes in CC tissues and normal tissues. Then the survival curve and boxplot were performed to visualize the relationships.

Identification of candidate small molecules
-------------------------------------------

The CC gene signature was used to query CMap to find potential drugs for use in patients.[@b21-cmar-10-3533] CMap is an in silico method to predict potential drugs that could possibly reverse, or induce, the biological state encoded in particular gene expression signatures. The common differently expressed probesets in GSE7803 and GSE9750 between CC samples and healthy controls were divided into upregulated and downregulated groups. Then, these probesets were used to query the CMap database. Finally, the enrichment score representing similarity was calculated, ranging from −1 to 1. A positive connectivity score indicates that a drug is able to induce the input signature in human cell lines. Conversely, a negative connectivity score indicates that a drug is able to reverse the input signature. Negative connectivity scores were investigated, which indicate potential therapeutic value. After rank ordering all instances, the connectivity score of various instances were filter by the number of instances (N\>10) and *P*-value (\<0.05).

Results
=======

DEGs identification
-------------------

The two mRNA expression profiles, including 54 patients with CC and 34 healthy individuals, were included in our study. Using a FDR \<0.05 and \|logFC\| \>1 as cutoff criteria, we extracted 443 and 848 differentially expressed probesets from the expression profile datasets GSE7803 and GSE9750, respectively. In GSE7803, 212 unregulated probes and 231 downregulated probes were identified. A total of 376 unregulated probes and 472 downregulated probes were identified in GSE9750. After being overlapped, the common 149 upregulated and 146 downregulated probesets corresponding to 145 upregulated and 135 downregulated genes were identified from the two profile datasets ([Table S1](#SD1-cmar-10-3533){ref-type="supplementary-material"}).

CC significant pathways evaluation
----------------------------------

A total of 16 pathways with adjusted *P*-value \<0.05 were found enriched including 10 upregulated and 6 downregulated pathways ([Table 1](#t1-cmar-10-3533){ref-type="table"}). The most significant upregulated pathway was cell cycle; the other significant pathways included DNA replication, oocyte meiosis, p53 signaling pathway, microRNAs in cancer, and cellular senescence. The downregulated pathways included arachidonic acid metabolism, serotonergic synapse, gap junction, estrogen signaling pathway, signaling pathways regulating pluripotency of stem cells, and proteoglycans in cancer ([Figure 1A](#f1-cmar-10-3533){ref-type="fig"}). In order to consider the potentially biological complexities in which a gene may belong to multiple pathways and provide information of numeric changes, we constructed pathway--gene networks to extract the complex association ([Figure 1B, C](#f1-cmar-10-3533){ref-type="fig"}). Cell cycle pathway contained the most significant genes in the network.

PPI network construction
------------------------

STRING was used for mining proteins expressed by DEGs which can interact with others. At a combined score \>0.4, a total of 222 DEGs (118 upregulated and 104 downregulated genes) among the 280 commonly altered DEGs were filtered into the DEGs PPI network, containing 222 nodes and 2,111 edges ([Figure 2A](#f2-cmar-10-3533){ref-type="fig"}). NetworkAnalyzer app in Cyto-scape was used to calculate the node degree.[@b25-cmar-10-3533] The genes CDK1, PCNA, TOP2A, CCNB1, RFC4, MAD2L1, NDC80, CCNB2, AURKA, TYMS, MCM2, FEN1, RRM2, NCAPG, TTK, PRC1, MCM4, ZWINT, DTL, and MCM6 were the most significant 20 node degree genes and were selected as the hub nodes, since they might play important roles in CC progression ([Figure 2B](#f2-cmar-10-3533){ref-type="fig"}).

Key gene signatures identification in CC
----------------------------------------

Compared with KEGG enrichment genes, 13 of the top 20 nodes in the PPI network, including AURKA, CCNB1, CCNB2, CDK1, FEN1, MAD2L1, MCM2, MCM4, MCM6, PCNA, RFC4, RRM2, and TTK were found as key genes. Further survival analyses on these key genes were employed to evaluate their effects on CC patients' survival using GEPIA. Expression levels of *MCM2*, *PCNA*, *RFC4*, and *RRM2* were significantly related to the OS of patients with cervical squamous cancer (*P*\<0.05). High expression of *MCM2*, *PCNA*, and *RFC4* could result in a high survival rate, and increased *RRM2* expression in CC was significantly associated with shorter patients' survival ([Figure 3A--D](#f3-cmar-10-3533){ref-type="fig"}). The expression of these four genes was significantly higher in CC tissues compared to that of normal tissues (*P*\<0.01; [Figure 3E--H](#f3-cmar-10-3533){ref-type="fig"}). Together, the high level of these four genes might represent the important prognostic factor to predict the survival of CC. GSE63514 was used to validate *RRM2* mRNA expression. The results showed that *RRM2* expression was significantly higher in CC compared to that of normal tissues (*P*\<0.01; [Figure 4A](#f4-cmar-10-3533){ref-type="fig"}). The PPI network based on RRM2 found that PCNA and RFC4 have a close relationship with RRM2, and most of the proteins in the network were related to cell cycle ([Figure 4B](#f4-cmar-10-3533){ref-type="fig"}).

Related small molecule drugs screening
--------------------------------------

In order to screen out small molecule drugs, consistent differently expressed probesets between CC samples and healthy controls were analyzed with CMap. The related small molecules with highly significant correlations are listed in [Table 2](#t2-cmar-10-3533){ref-type="table"}. Among these molecules, trichostatin A (TSA), tanespimycin, vorinostat, trifluoperazine, prochlorperazine, and thioridazine showed higher negative correlation and the potential to treat CC.

Discussion
==========

Driver genes play vital roles during stages of cancer progression. Although many studies on CC development are available, more efforts are needed to identify driver genes and candidate drugs that may shed light on CC treatments. This study integrated two gene profile datasets based on Affymetrix Human Genome U133A Array, utilized bioinformatics methods to analyze these datasets, and identified 280 commonly changed DEGs (145 upregulated and 135 downregulated). Pathway enrichment analysis indicated that cell cycle, DNA replication, oocyte meiosis, p53 signaling pathway, cellular senescence, and DNA repair-relevant biological pathways were overrepresented among the upregulated genes. The PPI network was constructed including 222 nodes/DEGs and 2,111 edges. Thirteen key genes were identified and chosen for survival analysis. *MCM2*, *PCNA*, *RFC4*, and *RRM2* were clearly related to the prognosis of patients. In addition, small molecules that can provide new insights in CC therapeutic studies were identified.

Many researchers have found that four key genes were involved in cell cycle, participating in tumorigenesis and tumor proliferation. MCM2 has been studied in a wide range of human malignancies and is associated with tumor histopathological grade in several malignancies, including colon, oral cavity, ovarian, urothelial, and non-small cell lung carcinoma.[@b30-cmar-10-3533]--[@b34-cmar-10-3533] In cervical carcinoma and precancerous lesions, MCM2 is overexpressed and positively correlated with high risk types of HPV.[@b35-cmar-10-3533] Amaro Filho et al also reported an increasing expression of MCM2 in invasive CC compared to control, but they suggested that MCM2 is not a good biomarker when comparing the different clinical stages of CC.[@b36-cmar-10-3533] PCNA acts as a central coordinator of DNA transactions by providing a multivalent interaction surface for factors involved in DNA replication and cell cycle regulation. Owing to its function, PCNA has been widely used as a tumor marker for cancer cell progression and patient prognosis.[@b37-cmar-10-3533]--[@b39-cmar-10-3533] A recent systematic literature review found that the expression of PCNA is significantly associated with poor 5-year survival, International Federation of Gynecology and Obstetrics stage, or WHO grade, suggesting its use as a valuable prognostic and diagnostic biomarker in CC and gliomas.[@b40-cmar-10-3533] RFC4 is involved in cancer. Knockdown of *RFC4* in HepG2 cells induces apoptosis.[@b41-cmar-10-3533] Similar results were discovered in breast carcinoma.[@b42-cmar-10-3533] In colorectal cancer, overexpression of RFC4 is associated with tumor progression and poor survival outcome.[@b43-cmar-10-3533] Additionally, with gene network reconstruction, RFC4 is regarded as one of the main drivers in cell cycle network in CC.[@b44-cmar-10-3533] Together with our results, *MCM2*, *PCNA*, and *RFC4* were significantly upregulated in CC compared with normal samples, and in CC patients, the survival rate was positively correlated with the high expression of these genes.

RRM2 is markedly upregulated in many patients' cancer types and indeed acts as an oncogene.[@b45-cmar-10-3533] *RRM2* knockdown reduces cell proliferation and invasive ability in gastric cancer and pancreatic adenocarcinoma.[@b46-cmar-10-3533],[@b47-cmar-10-3533] Wang et al reported that RRM2 expression inhibition significantly increases apoptosis, promotes cell cycle arrest at the G1 phase, and inhibits tumor formation in CC nude mice transplant models.[@b48-cmar-10-3533] Several studies showed that RRM2 is an independent prognostic factor and may predict poor survival in ovarian cancer, bladder cancer, breast cancer, and CC.[@b49-cmar-10-3533]--[@b52-cmar-10-3533] In this study, according to the PPI network, RRM2 closely interacts with PCNA and RFC4 involved in CC progression. Therefore, a further exploration of cell cycle and related genes was of enormous significance.

Consistent with our results, recent studies have also reported the identification of DEGs in CC. van Dam et al used three publicly available Affymetrix gene expression datasets (GSE5787, GSE7803, and GSE9750) and identified five cancer hallmarks enriched pathways in CC, showing that cell cycle deregulation is the major component of CC biology. They also identified seven probesets that were highly expressed in both CIN3 samples compared to normal samples and in cancer samples compared to CIN3 samples. From these probesets, six genes (*AURKA*, *DTL*, *HMGB3*, *KIF2C*, *NEK2*, and *RFC4*) were overexpressed in CC cell lines compared to cancer samples, suggesting their potential role as biomarkers in CC early diagnosis.[@b53-cmar-10-3533] One of these genes, such as *RFC4*, was also identified in our study. Furthermore, our conclusion generated from both expression and survival analysis suggested that *RFC4* might have a prognostic value. Another report from Li et al was based on TCGA data.[@b54-cmar-10-3533] They found that *MCM2*, *MCM4*, *MCM5*, *PCNA*, and *RNASEH2A* participating in DNA replication pathway might be prognostic biomarkers in CC patients. *MCM2* and *PCNA* were also found in our results.

Several small molecules with potential therapeutic efficacy against CC were identified. The most significant small molecules in our result have been reported to display anticancer activity. TSA, as a histone deacetylase (HDAC) inhibitor, shows a potential therapeutic effect in various types of cancer cells, when combined with radiotherapy or chemotherapy.[@b55-cmar-10-3533],[@b56-cmar-10-3533] In particular, TSA and its hydroxamate analogs can effectively and selectively induce tumor growth arrest at very low concentrations.[@b57-cmar-10-3533] Additionally, TSA can inhibit HeLa cells growth via Bcl-2-mediated and caspase-dependent apoptosis.[@b58-cmar-10-3533] Vorinostat is a hydroxamate-based pan-HDAC inhibitor also known as suberoylanilide hydroxamic acid used for the treatment of cutaneous T-cell lymphoma.[@b59-cmar-10-3533] In HeLa cell, both mRNA and protein levels of HPV18 E6 and E7 were reduced after vorinostat treatment.[@b60-cmar-10-3533] Furthermore, vorinostat promotes SiHa apoptosis through upregulation of p21 and Bax mRNA and protein, leading to cell cycle arrest in G0/G1 phase.[@b61-cmar-10-3533] Thioridazine, a derivative of phenothiazine, displays anticancer abilities in a variety of cancer types and can reverse multidrug resistance.[@b62-cmar-10-3533]--[@b64-cmar-10-3533] Kang et al found that thioridazine can inhibit the PI3K/Akt/mTOR/p70S6K signaling pathway and exert cytotoxic effect on CC cells by inducing cell cycle arrest and apoptosis.[@b65-cmar-10-3533] Thus, we might suppose that these identified drugs could play certain roles to combat CC.

Conclusion
==========

Using bioinformatics analysis, 280 DEGs were identified, which were significantly enriched in several pathways, mainly associated with cell cycle, DNA replication, oocyte meiosis, p53 signaling pathway, and cellular senescence. We also identified key genes including *MCM2*, *PCNA*, *RFC4*, and *RRM2* that might play important roles in CC and that might represent novel biomarkers in CC diagnosis, prognosis, and therapy. Additionally, a group of small molecules was identified that might be exploited as adjuvant drugs for improved therapeutics for CC. However, further investigations are required to validate the predicted drugs.

Supplementary material
======================

###### 

Common dysregulated probes identified in GSE7803 and GSE9750

  Number          Probe name     Gene symbol                                              logFC     Adjusted *P*-value               
  --------------- -------------- -------------------------------------------------------- --------- -------------------- ----------- -----------
  Upregulated                                                                                                                        
  1               200783_s\_at   *STMN1*                                                  1.0912    1.0985               4.11E--05   1.25E--04
  2               201202_at      *PCNA*                                                   1.8714    1.3752               4.41E--09   2.87E--05
  3               201291_s\_at   *TOP2A*                                                  2.4680    2.4862               1.05E--08   5.16E--06
  4               201292_at      *TOP2A*                                                  1.2403    2.0680               1.71E--06   2.30E--04
  5               201506_at      *TGFBI*                                                  1.1157    1.1297               2.21E--02   1.60E--02
  6               201555_at      *MCM3*                                                   1.0145    1.2759               3.14E--07   5.41E--07
  7               201589_at      *SMC1A*                                                  1.3907    1.0445               5.43E--06   8.52E--05
  8               201650_at      *KRT19*                                                  1.5763    2.3797               2.89E--02   8.95E--05
  9               201663_s\_at   *SMC4*                                                   1.4923    1.5673               1.60E--06   4.31E--05
  10              201664_at      *SMC4*                                                   1.7038    1.8408               9.71E--06   7.08E--06
  11              201697_s\_at   *DNMT1*                                                  1.0219    1.2128               1.05E--08   4.10E--09
  12              201761_at      *MTHFD2*                                                 1.6111    1.3783               4.73E--05   4.37E--05
  13              201839_s\_at   *EPCAM*                                                  1.6182    2.2101               3.36E--04   1.82E--04
  14              201890_at      *RRM2*                                                   1.7698    2.3342               1.05E--05   1.44E--06
  15              201897_s\_at   *CKS1B*                                                  1.3398    1.2246               1.04E--06   4.26E--05
  16              201930_at      *MCM6*                                                   1.5487    1.4628               6.91E--09   1.25E--08
  17              201970_s\_at   *NASP*                                                   1.3464    1.1522               1.38E--08   9.44E--09
  18              202107_s\_at   *MCM2*                                                   1.7296    2.2864               1.91E--08   7.29E--10
  19              202219_at      *SLC6A8*                                                 1.4325    1.8698               5.38E--03   2.75E--05
  20              202234_s\_at   *SLC16A1*                                                1.3561    1.2683               4.70E--03   7.50E--04
  21              202338_at      *TK1*                                                    1.1038    1.2846               2.40E--06   2.91E--06
  22              202412_s\_at   *USP1*                                                   1.0775    1.2056               3.24E--04   3.54E--04
  23              202430_s\_at   *PLSCR1*                                                 1.2889    1.1148               1.29E--04   7.10E--05
  24              202446_s\_at   *PLSCR1*                                                 1.6150    1.5934               1.16E--06   1.41E--06
  25              202503_s\_at   *PCLAF*                                                  2.0118    1.9842               2.33E--10   1.18E--04
  26              202589_at      *TYMS*                                                   1.5263    2.2375               1.95E--04   8.52E--08
  27              202619_s\_at   *PLOD2*                                                  1.8339    2.0812               1.44E--06   1.41E--07
  28              202620_s\_at   *PLOD2*                                                  2.8767    2.2084               3.54E--09   5.09E--07
  29              202625_at      *LYN*                                                    1.1767    1.4027               1.20E--03   2.09E--03
  30              202626_s\_at   *LYN*                                                    1.5737    1.7521               1.07E--03   8.51E--05
  31              202633_at      *TOPBP1*                                                 1.6677    1.4670               3.67E--07   7.76E--07
  32              202666_s\_at   *ACTL6A*                                                 1.5525    1.1292               9.46E--07   1.46E--03
  33              202688_at      *TNFSF10*                                                1.0878    1.1141               3.63E--02   3.00E--02
  34              202705_at      *CCNB2*                                                  1.0405    1.7114               7.17E--05   8.58E--06
  35              202854_at      *HPRT1*                                                  1.0911    1.2618               2.75E--04   7.59E--05
  36              202859_x\_at   *CXCL8*                                                  1.5100    2.7989               1.66E--02   3.86E--04
  37              202887_s\_at   *DDIT4*                                                  1.0791    2.1221               4.05E--02   3.21E--04
  38              202983_at      *HLTF*                                                   2.0242    1.2271               4.08E--07   2.36E--03
  39              203046_s\_at   *TIMELESS*                                               1.1641    1.4554               1.96E--08   1.55E--07
  40              203209_at      *RFC5*                                                   1.5612    1.2914               1.93E--07   7.95E--06
  41              203213_at      *CDK1*                                                   1.5427    1.9989               1.11E--05   9.35E--06
  42              203358_s\_at   *EZH2*                                                   1.6144    1.6656               3.31E--07   3.91E--05
  43              203362_s\_at   *MAD2L1*                                                 1.0749    1.2051               4.94E--03   1.40E--02
  44              203554_x\_at   *PTTG1*                                                  1.2746    1.3424               1.32E--05   3.11E--03
  45              203693_s\_at   *E2F3*                                                   1.2182    1.2321               1.16E--06   1.28E--04
  46              203744_at      *HMGB3*                                                  1.1938    1.6479               3.01E--04   1.41E--07
  47              203755_at      *BUB1B*                                                  1.0860    1.8703               3.34E--07   1.96E--06
  48              203764_at      *DLGAP5*                                                 1.4536    2.2334               3.73E--05   9.69E--05
  49              203819_s\_at   *IGF2BP3*                                                1.2319    1.4909               2.75E--02   2.22E--02
  50              203856_at      *VRK1*                                                   1.1485    1.1641               4.00E--06   2.15E--04
  51              204023_at      *RFC4*                                                   1.5116    2.1996               7.47E--08   2.54E--07
  52              204026_s\_at   *ZWINT*                                                  1.5906    1.8649               2.05E--04   2.07E--05
  53              204092_s\_at   *AURKA*                                                  1.1672    1.0470               1.39E--07   2.36E--05
  54              204146_at      *RAD51AP1*                                               1.6216    1.6478               4.26E--07   8.74E--05
  55              204159_at      *CDKN2C*                                                 1.5231    1.2248               2.07E--03   3.73E--03
  56              204162_at      *NDC80*                                                  1.5684    1.3280               9.05E--05   1.03E--03
  57              204170_s\_at   *CKS2*                                                   1.4786    1.5687               6.24E--05   5.32E--03
  58              204416_x\_at   *APOC1*                                                  1.0620    1.3204               8.58E--03   9.07E--04
  59              204439_at      *IFI44L*                                                 1.5993    1.4595               4.00E--02   5.25E--02
  60              204510_at      *CDC7*                                                   1.3374    1.6750               1.88E--06   2.38E--06
  61              204580_at      *MMP12*                                                  1.6409    2.9620               2.22E--03   2.97E--05
  62              204641_at      *NEK2*                                                   1.3957    2.1694               6.79E--08   2.33E--07
  63              204698_at      *ISG20*                                                  1.0250    1.3923               6.87E--04   1.78E--05
  64              204767_s\_at   *FEN1*                                                   1.4080    1.7083               1.31E--09   3.37E--07
  65              204784_s\_at   *MLF1*                                                   1.6420    1.6891               6.24E--05   3.01E--04
  66              204822_at      *TTK*                                                    1.4460    1.4235               7.52E--08   2.45E--03
  67              204825_at      *MELK*                                                   1.8745    1.9957               2.90E--07   3.60E--07
  68              205034_at      *CCNE2*                                                  1.3408    1.7091               4.18E--04   5.08E--04
  69              205157_s\_at   *KRT17*                                                  1.5725    3.3509               2.32E--02   1.54E--05
  70              205339_at      *STIL*                                                   1.0641    1.5078               1.16E--06   9.67E--08
  71              205449_at      *SAC3D1*                                                 1.3483    1.1408               4.86E--05   2.80E--04
  72              205479_s\_at   *PLAU*                                                   1.2262    1.4554               1.65E--03   4.38E--04
  73              205483_s\_at   *ISG15*                                                  1.3717    2.0505               1.65E--02   5.73E--04
  74              205569_at      *LAMP3*                                                  1.7550    1.2873               4.09E--04   2.57E--02
  75              205691_at      *SYNGR3*                                                 1.2198    1.4950               5.72E--04   3.29E--04
  76              205910_s\_at   *CEL*                                                    1.8737    1.2510               1.62E--02   3.08E--02
  77              206102_at      *GINS1*                                                  1.6544    1.9896               6.95E--05   4.57E--06
  78              206332_s\_at   *IFI16*                                                  1.5947    1.2876               8.99E--07   2.56E--04
  79              206513_at      *AIM2*                                                   2.0306    2.3769               1.22E--03   2.74E--03
  80              206546_at      *SYCP2*                                                  1.3491    2.3512               2.17E--03   5.99E--05
  81              206632_s\_at   *APOBEC3A*, *APOBEC3B*                                   2.9688    1.9572               1.68E--08   2.46E--04
  82              206858_s\_at   *HOXC6*                                                  2.1365    1.4749               1.66E--05   1.02E--03
  83              207039_at      *CDKN2A*                                                 4.6085    4.0377               3.50E--14   1.62E--14
  84              207165_at      *HMMR*                                                   1.4593    1.0523               2.62E--06   1.30E--02
  85              207332_s\_at   *TFRC*                                                   1.2833    1.3954               4.66E--04   5.87E--03
  86              207828_s\_at   *CENPF*                                                  1.4100    1.9877               1.36E--07   9.05E--08
  87              208079_s\_at   *AURKA*                                                  2.2857    2.0803               1.85E--09   5.77E--08
  88              208691_at      *TFRC*                                                   1.5192    1.4901               6.53E--06   5.22E--04
  89              208795_s\_at   *MCM7*, *MIR25*, *MIR93*, *MIR106B*                      1.1151    1.3206               1.55E--07   2.44E--05
  90              208808_s\_at   *HMGB2*                                                  1.5215    1.1577               8.56E--07   7.41E--04
  91              208965_s\_at   *IFI16*                                                  1.4542    1.3939               2.56E--05   6.32E--04
  92              208966_x\_at   *IFI16*                                                  1.7717    1.3388               4.13E--07   6.92E--05
  93              208998_at      *UCP2*                                                   1.9521    1.1262               2.31E--05   2.83E--03
  94              209398_at      *HIST1H1C*                                               1.1786    1.2497               5.37E--03   7.31E--03
  95              209408_at      *KIF2C*                                                  1.4768    1.5638               1.85E--09   4.49E--09
  96              209579_s\_at   *MBD4*                                                   1.2877    1.1884               6.26E--07   6.34E--05
  97              209773_s\_at   *RRM2*                                                   1.2805    1.9504               2.40E--03   6.29E--05
  98              209875_s\_at   *SPP1*                                                   2.5457    3.4037               3.80E--04   3.18E--06
  99              209900_s\_at   *SLC16A1*                                                1.5149    1.2504               1.45E--03   1.73E--03
  100             209969_s\_at   *STAT1*                                                  1.8886    2.1349               6.82E--04   4.07E--04
  101             210580_x\_at   *SLX1A-SULT1A3*, *SLX1B-SULT1A4*, *SULT1A3*, *SULT1A4*   1.0598    1.0491               1.80E--03   1.19E--03
  102             212022_s\_at   *MKI67*                                                  1.4831    1.5781               8.11E--07   1.81E--06
  103             212236_x\_at   *KRT17*                                                  1.3508    2.7588               3.84E--02   7.95E--06
  104             212255_s\_at   *ATP2C1*                                                 1.0824    1.0588               1.60E--04   8.54E--05
  105             212297_at      *ATP13A3*                                                1.4423    1.1315               1.69E--06   6.46E--05
  106             212621_at      *NEMP1*                                                  1.4685    1.2100               1.63E--07   2.29E--07
  107             212840_at      *UBXN7*                                                  1.0252    1.0213               1.25E--04   1.36E--03
  108             212977_at      *ACKR3*                                                  2.0327    1.2298               4.91E--03   5.31E--02
  109             213007_at      *FANCI*                                                  1.3983    1.6034               2.79E--07   2.80E--07
  110             213008_at      *FANCI*                                                  1.0861    1.6205               4.34E--05   4.91E--08
  111             213164_at      *SLC5A3*                                                 1.0329    1.0596               2.97E--05   4.04E--04
  112             213457_at      *MFHAS1*                                                 1.0606    1.0186               3.06E--02   2.25E--03
  113             213693_s\_at   *MUC1*                                                   1.2200    1.9901               3.72E--02   4.37E--04
  114             213951_s\_at   *PSMC3IP*                                                1.2274    1.2423               1.92E--07   2.52E--07
  115             213988_s\_at   *SAT1*                                                   1.1293    1.0600               2.52E--03   7.87E--04
  116             214329_x\_at   *TNFSF10*                                                2.3354    1.2571               6.72E--06   1.12E--02
  117             214710_s\_at   *CCNB1*                                                  1.2879    1.7956               3.73E--05   1.97E--04
  118             215388_s\_at   *CFH*, *CFHR1*                                           1.4348    1.0577               1.61E--02   4.50E--02
  119             216237_s\_at   *MCM5*                                                   1.5683    2.0746               1.77E--08   8.15E--11
  120             217885_at      *IPO9*                                                   1.1126    1.0339               1.76E--07   1.89E--05
  121             217901_at      *DSG2*                                                   1.3065    2.5311               6.24E--05   3.60E--07
  122             218009_s\_at   *PRC1*                                                   1.6401    2.1259               5.88E--08   1.78E--06
  123             218039_at      *NUSAP1*                                                 2.1401    2.3735               7.34E--09   5.69E--06
  124             218350_s\_at   *GMNN*                                                   1.7878    1.8225               3.13E--07   2.66E--06
  125             218355_at      *KIF4A*                                                  1.0153    1.7434               2.38E--06   2.89E--07
  126             218542_at      *CEP55*                                                  1.3865    2.4903               2.46E--06   2.29E--07
  127             218585_s\_at   *DTL*                                                    1.3800    2.8428               2.32E--06   4.81E--09
  128             218662_s\_at   *NCAPG*                                                  1.6736    1.5539               4.30E--06   1.30E--04
  129             218757_s\_at   *UPF3B*                                                  1.3448    1.0318               6.72E--05   2.68E--05
  130             218883_s\_at   *CENPU*                                                  1.2494    1.5454               7.55E--04   3.91E--03
  131             219014_at      *PLAC8*                                                  1.2330    1.4057               2.84E--02   3.55E--02
  132             219105_x\_at   *ORC6*                                                   1.0780    1.0908               2.10E--04   5.03E--07
  133             219258_at      *TIPIN*                                                  1.1365    1.4832               3.91E--07   1.27E--06
  134             219306_at      *KIF15*                                                  1.0990    1.0348               1.84E--04   1.03E--03
  135             219507_at      *RSRC1*                                                  1.3864    1.2573               3.27E--05   3.86E--04
  136             219787_s\_at   *ECT2*                                                   2.8139    2.5551               1.00E--08   1.37E--06
  137             219918_s\_at   *ASPM*                                                   1.2168    1.9490               4.36E--05   2.25E--04
  138             219959_at      *MOCOS*                                                  1.0344    1.9971               3.59E--03   1.67E--05
  139             219978_s\_at   *NUSAP1*                                                 1.1780    1.6455               8.94E--04   6.82E--05
  140             219990_at      *E2F8*                                                   1.4188    1.1301               1.17E--04   1.10E--03
  141             220239_at      *KLHL7*                                                  1.0503    1.0053               3.05E--03   1.40E--03
  142             221046_s\_at   *GTPBP8*                                                 1.0722    1.0602               1.44E--06   4.04E--04
  143             221521_s\_at   *GINS2*                                                  1.4631    1.8407               8.85E--06   3.27E--06
  144             222036_s\_at   *MCM4*                                                   1.0134    1.8445               1.71E--06   1.67E--06
  145             222039_at      *KIF18B*                                                 1.5126    1.0619               7.17E--09   2.91E--06
  146             222077_s\_at   *RACGAP1*                                                1.5482    1.6939               2.69E--06   5.07E--05
  147             222380_s\_at   *PDCD6*                                                  1.0922    1.0579               3.96E--04   1.18E--02
  148             31845_at       *ELF4*                                                   1.2212    1.0448               2.96E--05   1.00E--05
  149             33304_at       *ISG20*                                                  1.1281    1.1279               1.62E--04   7.59E--05
  Downregulated                                                                                                                      
  1               200795_at      *SPARCL1*                                                −2.6933   −2.5139              3.39E--04   2.05E--04
  2               201012_at      *ANXA1*                                                  −1.6637   −1.2447              1.15E--03   1.28E--03
  3               201041_s\_at   *DUSP1*                                                  −1.7177   −1.2448              7.16E--03   3.26E--02
  4               201201_at      *CSTB*                                                   −1.6745   −1.0817              6.75E--04   2.05E--04
  5               201312_s\_at   *SH3BGRL*                                                −1.0735   −2.0334              1.43E--02   3.28E--04
  6               201324_at      *EMP1*                                                   −2.5006   −2.0144              1.69E--05   7.39E--05
  7               201325_s\_at   *EMP1*                                                   −2.8729   −2.3264              2.29E--08   3.96E--06
  8               201348_at      *GPX3*                                                   −1.6408   −2.9297              1.32E--05   9.66E--08
  9               201667_at      *GJA1*                                                   −2.1421   −2.0359              3.83E--03   6.21E--03
  10              201735_s\_at   *CLCN3*                                                  −1.1179   −1.0850              1.09E--03   1.89E--03
  11              201811_x\_at   *SH3BP5*                                                 −1.2423   −1.3642              3.25E--03   5.04E--03
  12              201893_x\_at   *DCN*                                                    −1.2951   −2.2495              1.17E--03   7.34E--04
  13              202539_s\_at   *HMGCR*                                                  −1.0673   −1.3111              2.12E--03   1.05E--02
  14              202575_at      *CRABP2*                                                 −1.1350   −1.9855              2.03E--07   1.63E--03
  15              202660_at      *ITPR2*                                                  −1.2894   −1.0723              6.71E--07   2.03E--04
  16              202668_at      *EFNB2*                                                  −1.0648   −1.0430              2.83E--03   1.00E--02
  17              202768_at      *FOSB*                                                   −1.6730   −2.2309              6.70E--03   5.21E--03
  18              202967_at      *GSTA4*                                                  −1.4779   −1.8389              4.26E--07   2.57E--04
  19              203407_at      *PPL*                                                    −1.5681   −1.8813              3.47E--05   3.27E--06
  20              203535_at      *S100A9*                                                 −1.9766   −1.2926              8.14E--03   1.86E--02
  21              203585_at      *ZNF185*                                                 −1.3599   −1.3991              1.52E--03   4.20E--05
  22              203638_s\_at   *FGFR2*                                                  −1.3240   −1.5564              3.23E--04   7.27E--04
  23              203700_s\_at   *DIO2*                                                   −1.3828   −1.1342              1.94E--03   4.10E--02
  24              203913_s\_at   *HPGD*                                                   −1.7678   −2.7646              5.41E--05   3.98E--05
  25              203914_x\_at   *HPGD*                                                   −2.4427   −2.7244              1.11E--05   2.65E--05
  26              203961_at      *NEBL*                                                   −1.4367   −1.5881              2.34E--03   5.38E--03
  27              204141_at      *TUBB2A*                                                 −1.7240   −1.5928              1.18E--03   1.89E--04
  28              204256_at      *ELOVL6*                                                 −1.3219   −1.1355              4.57E--03   4.75E--02
  29              204284_at      *PPP1R3C*                                                −2.6784   −3.7692              4.26E--07   2.33E--09
  30              204359_at      *FLRT2*                                                  −1.1097   −2.2141              5.71E--03   4.36E--05
  31              204451_at      *FZD1*                                                   −1.1135   −1.0997              1.15E--05   1.01E--04
  32              204731_at      *TGFBR3*                                                 −1.3493   −1.8325              7.17E--03   4.04E--04
  33              204750_s\_at   *DSC2*                                                   −2.0225   −1.1059              2.83E--04   4.70E--02
  34              204751_x\_at   *DSC2*                                                   −1.9548   −2.2472              2.98E--04   1.15E--04
  35              204777_s\_at   *MAL*                                                    −4.8179   −5.7789              9.50E--07   1.62E--14
  36              204952_at      *LYPD3*                                                  −1.5886   −1.7448              1.08E--04   4.43E--04
  37              205064_at      *SPRR1B*                                                 −2.2769   −2.7744              1.39E--03   1.20E--02
  38              205185_at      *SPINK5*                                                 −3.8683   −3.6665              3.46E--07   3.15E--05
  39              205225_at      *ESR1*                                                   −3.0458   −2.7160              9.37E--06   1.54E--05
  40              205239_at      *AREG*                                                   −1.8099   −1.5361              3.96E--02   1.14E--03
  41              205363_at      *BBOX1*                                                  −1.8640   −2.8822              2.54E--09   1.27E--05
  42              205382_s\_at   *CFD*                                                    −2.1856   −2.5747              9.39E--07   1.20E--06
  43              205470_s\_at   *KLK11*                                                  −1.9196   −2.3007              8.84E--08   1.78E--03
  44              205726_at      *DIAPH2*                                                 −1.0814   −1.4450              1.17E--03   1.34E--04
  45              205759_s\_at   *SULT2B1*                                                −1.2047   −1.2198              1.04E--06   5.73E--03
  46              205765_at      *CYP3A5*                                                 −1.8262   −1.1731              3.95E--06   5.05E--03
  47              205767_at      *EREG*                                                   −1.6854   −2.1525              1.38E--04   8.11E--05
  48              205778_at      *KLK7*                                                   −1.3998   −1.7611              4.35E--03   1.13E--02
  49              205862_at      *GREB1*                                                  −1.5579   −1.8147              1.16E--03   1.94E--06
  50              205863_at      *S100A12*                                                −1.2720   −2.0771              4.51E--03   6.18E--04
  51              205900_at      *KRT1*                                                   −4.8450   −5.1604              9.91E--10   1.22E--06
  52              206008_at      *TGM1*                                                   −1.3988   −1.4672              3.53E--03   2.12E--02
  53              206104_at      *ISL1*                                                   −1.8146   −1.8069              4.46E--05   4.23E--06
  54              206295_at      *IL18*                                                   −1.8318   −1.1817              9.99E--08   1.78E--02
  55              206400_at      *LGALS7*, *LGALS7B*                                      −1.2508   −1.7496              1.50E--02   2.32E--02
  56              206605_at      *ENDOU*                                                  −2.0623   −3.5113              1.38E--10   3.61E--09
  57              206642_at      *DSG1*                                                   −3.6072   −4.3758              2.39E--09   6.70E--07
  58              206714_at      *ALOX15B*                                                −1.2685   −1.0664              8.35E--04   2.03E--02
  59              206884_s\_at   *SCEL*                                                   −2.4970   −3.2369              4.84E--05   3.50E--06
  60              207002_s\_at   *PLAGL1*                                                 −1.1346   −1.2887              9.02E--03   5.44E--04
  61              207023_x\_at   *KRT10*                                                  −1.6054   −1.6701              5.50E--03   1.32E--03
  62              207057_at      *SLC16A7*                                                −1.5167   −1.0148              2.07E--06   2.86E--02
  63              207206_s\_at   *ALOX12*                                                 −2.4692   −2.9129              2.60E--07   5.89E--06
  64              207381_at      *ALOX12B*                                                −1.8250   −1.5189              8.81E--07   1.92E--02
  65              207463_x\_at   *PRSS3*                                                  −1.6595   −2.2675              1.69E--05   7.14E--04
  66              207480_s\_at   *MEIS2*                                                  −1.1053   −1.4587              8.12E--03   3.86E--03
  67              207602_at      *TMPRSS11D*                                              −1.7796   −2.2185              1.94E--04   1.24E--03
  68              207720_at      *LOR*                                                    −1.5659   −1.7321              9.03E--03   5.54E--03
  69              207761_s\_at   *METTL7A*                                                −1.4377   −1.7274              1.64E--02   1.54E--03
  70              207802_at      *CRISP3*                                                 −3.5353   −4.9186              8.56E--07   2.03E--08
  71              207908_at      *KRT2*                                                   −1.0700   −1.7438              7.77E--06   2.44E--04
  72              207935_s\_at   *KRT13*                                                  −3.3723   −3.4606              6.80E--04   5.75E--03
  73              208126_s\_at   *CYP2C18*                                                −1.0287   −1.2034              3.17E--04   2.53E--02
  74              208228_s\_at   *FGFR2*                                                  −1.1180   −1.5103              5.59E--03   2.23E--03
  75              208399_s\_at   *EDN3*                                                   −1.7159   −2.7146              2.90E--07   1.83E--07
  76              208539_x\_at   *SPRR2A*, *SPRR2B*, *SPRR2D*                             −1.0258   −3.4094              4.88E--03   2.74E--04
  77              208650_s\_at   *CD24*                                                   −1.6380   −1.0461              5.52E--03   9.70E--03
  78              208712_at      *CCND1*                                                  −1.7584   −1.3400              1.85E--09   1.70E--04
  79              209118_s\_at   *TUBA1A*                                                 −1.1814   −1.6618              3.70E--03   8.97E--04
  80              209126_x\_at   *KRT6A*, *KRT6B*                                         −1.0109   −1.7619              7.83E--03   3.16E--03
  81              209189_at      *FOS*                                                    −1.2550   −1.7443              6.40E--03   1.23E--02
  82              209242_at      *PEG3*                                                   −1.1185   −1.7051              1.60E--04   4.77E--05
  83              209250_at      *DEGS1*                                                  −1.6475   −1.0716              1.68E--04   4.35E--03
  84              209283_at      *CRYAB*                                                  −1.4519   −2.9331              4.29E--07   1.48E--09
  85              209291_at      *ID4*                                                    −2.2617   −1.7203              2.32E--06   1.04E--03
  86              209318_x\_at   *PLAGL1*                                                 −1.0631   −1.5734              2.80E--02   1.87E--03
  87              209335_at      *DCN*                                                    −1.6677   −2.5536              2.57E--03   3.04E--04
  88              209540_at      *IGF1*                                                   −1.1470   −2.0332              1.72E--02   5.42E--03
  89              209541_at      *IGF1*                                                   −1.4871   −2.5855              1.91E--03   2.83E--03
  90              209550_at      *NDN*                                                    −1.1674   −1.7010              4.80E--05   3.81E--04
  91              209569_x\_at   *NSG1*                                                   −1.3910   −1.9295              8.88E--08   1.28E--04
  92              209570_s\_at   *NSG1*                                                   −1.6985   −1.3952              1.95E--04   2.86E--05
  93              209605_at      *TST*                                                    −1.5512   −1.0193              1.42E--07   1.02E--02
  94              209687_at      *CXCL12*                                                 −1.6878   −3.5983              1.05E--03   1.57E--05
  95              210020_x\_at   *CALML3*                                                 −1.2936   −1.5506              2.22E--03   2.33E--02
  96              211423_s\_at   *SC5D*                                                   −1.0341   −1.1407              2.63E--04   2.14E--02
  97              211548_s\_at   *HPGD*                                                   −2.2811   −2.9565              9.06E--06   1.77E--05
  98              211549_s\_at   *HPGD*                                                   −1.5563   −1.6731              1.97E--05   2.01E--05
  99              211597_s\_at   *HOPX*                                                   −3.4727   −3.8543              1.85E--09   6.16E--10
  100             211748_x\_at   *PTGDS*                                                  −1.1759   −2.8281              6.75E--04   3.00E--05
  101             211813_x\_at   *DCN*                                                    −1.0371   −2.4546              5.80E--03   8.88E--05
  102             211896_s\_at   *DCN*                                                    −1.7222   −2.8559              4.39E--05   6.65E--04
  103             212099_at      *RHOB*                                                   −1.2852   −1.4439              1.59E--02   9.09E--03
  104             212187_x\_at   *PTGDS*                                                  −1.0762   −2.8519              1.63E--03   2.66E--05
  105             212230_at      *PLPP3*                                                  −1.2267   −1.8056              4.59E--03   2.70E--03
  106             212268_at      *SERPINB1*                                               −2.0739   −1.0263              1.49E--06   1.91E--02
  107             212593_s\_at   *PDCD4*, *MIR4680*                                       −1.0203   −1.0249              1.71E--06   6.53E--04
  108             213005_s\_at   *KANK1*                                                  −1.3237   −1.4490              2.32E--06   1.01E--04
  109             213240_s\_at   *KRT4*                                                   −4.3954   −3.6606              1.22E--05   4.69E--03
  110             213287_s\_at   *KRT10*                                                  −1.4603   −1.5958              6.51E--03   7.27E--04
  111             213421_x\_at   *PRSS3*                                                  −1.3548   −1.8542              1.74E--05   2.02E--03
  112             213680_at      *KRT6B*                                                  −1.9134   −1.6133              1.08E--02   4.60E--02
  113             213796_at      *SPRR1A*                                                 −2.5895   −3.5348              1.67E--02   2.67E--03
  114             213895_at      *EMP1*                                                   −1.5169   −1.8942              7.08E--07   1.20E--06
  115             214091_s\_at   *GPX3*                                                   −1.6787   −3.0400              6.10E--06   7.67E--08
  116             214247_s\_at   *DKK3*                                                   −1.7619   −1.4292              4.50E--04   1.56E--02
  117             214549_x\_at   *SPRR1A*                                                 −2.7653   −3.2505              1.35E--04   6.67E--04
  118             214599_at      *IVL*                                                    −2.6075   −2.2661              3.08E--05   4.70E--05
  119             214621_at      *GYS2*                                                   −1.6288   −1.5121              1.62E--04   9.55E--06
  120             214624_at      *UPK1A*                                                  −3.4453   −2.3695              1.95E--11   4.10E--09
  121             214696_at      *MIR22*, *MIR22HG*                                       −1.2503   −1.0092              9.91E--04   6.55E--04
  122             217845_x\_at   *HIGD1A*                                                 −1.1969   −1.1395              4.79E--04   1.22E--03
  123             218002_s\_at   *CXCL14*                                                 −2.3615   −2.3685              5.25E--03   2.29E--03
  124             218312_s\_at   *ZSCAN18*                                                −1.5418   −1.8495              2.07E--06   4.65E--06
  125             218502_s\_at   *TRPS1*                                                  −1.0972   −1.8370              2.27E--04   1.42E--06
  126             218677_at      *S100A14*                                                −1.2332   −1.0900              4.46E--05   2.11E--03
  127             218990_s\_at   *SPRR3*                                                  −3.8102   −4.0176              5.84E--05   5.09E--04
  128             219090_at      *SLC24A3*                                                −1.4945   −1.8096              2.33E--05   3.51E--05
  129             219267_at      *GLTP*                                                   −1.9362   −1.2742              5.88E--07   2.51E--03
  130             219304_s\_at   *PDGFD*                                                  −1.2399   −2.5374              1.71E--05   1.89E--09
  131             219554_at      *RHCG*                                                   −2.3009   −3.4518              1.07E--05   3.81E--05
  132             219648_at      *MREG*                                                   −1.1721   −1.0151              3.34E--06   2.70E--02
  133             219836_at      *ZBED2*                                                  −1.8152   −1.6920              4.01E--07   4.37E--04
  134             219995_s\_at   *ZNF750*                                                 −1.3202   −1.4628              3.99E--03   6.24E--03
  135             220026_at      *CLCA4*                                                  −1.7727   −2.3287              2.21E--02   2.67E--03
  136             220066_at      *NOD2*                                                   −1.2609   −1.3621              1.70E--05   8.88E--05
  137             220090_at      *CRNN*                                                   −4.8078   −6.4682              1.02E--11   7.05E--15
  138             220266_s\_at   *KLF4*                                                   −1.1657   −2.2531              4.46E--05   1.27E--04
  139             220403_s\_at   *TP53AIP1*                                               −1.2074   −1.2307              1.17E--03   1.28E--03
  140             220431_at      *TMPRSS11E*                                              −1.1214   −2.9572              3.59E--04   5.14E--04
  141             220620_at      *CRCT1*                                                  −2.6450   −4.1521              1.60E--06   6.43E--05
  142             220723_s\_at   *CWH43*                                                  −1.7748   −2.6534              4.41E--09   7.02E--07
  143             221667_s\_at   *HSPB8*                                                  −1.6989   −1.8139              7.42E--06   5.09E--07
  144             221841_s\_at   *KLF4*                                                   −2.1774   −2.2756              3.11E--05   2.90E--04
  145             221896_s\_at   *HIGD1A*                                                 −1.1638   −1.1978              7.06E--04   9.97E--04
  146             57588_at       *SLC24A3*                                                −1.1619   −1.5407              2.29E--05   1.32E--05

**Abbreviation:** FC, fold change.

This work was supported by grants from the National Natural Science Foundation of China (grant no 81360336), the Joint Special Funds for the Department of Science and Technology of Yunnan Province -- Kunming Medical University (grant no 2015FB017) and One Hundred Young and Middle - Aged Academic and Technical Backbone Project of Kunming Medical University (grant no. 60117190449).

**Disclosure**

The authors report no conflicts of interest in this work.

![Significantly enriched pathway terms associated to DEGs in CC.\
**Notes:** (**A**) KEGG pathways in CC DEGs enrichment analysis. (**B**) Upregulated pathway--gene network including 35 upregulated genes and 10 pathways. (**C**) Downregulated pathway--gene network including 26 downregulated genes and 6 pathways.\
**Abbreviations:** CC, cervical cancer; DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes; HTLV-I, human T-lymphotropic virus type 1.](cmar-10-3533Fig1){#f1-cmar-10-3533}

![PPI network analysis.\
**Notes:** (**A**) Using the STRING online database, a total of 222 DEGs (118 upregulated in red standing for upregulation and 104 downregulated genes in green standing for downregulation) were filtered into the DEGs PPI network. Bigger nodes represent genes with more links. (**B**) Degree of the top 20 nodes in the PPI network. All these nodes are upregulated genes.\
**Abbreviations:** DEGS, differentially expressed genes; PPI, protein--protein interaction.](cmar-10-3533Fig2){#f2-cmar-10-3533}

![Survival curves and expression boxplots of key genes using GEPIA website.\
**Notes:** (**A--D**) Expression level of *MCM2, PCNA, RFC4, and RRM2* was significantly related to the overall survival of patients with cervical squamous cancer (*P*\<0.05). (**E--H**) *MCM2*, *PCNA*, *RFC4*, and *RRM2* were significantly upregulated in cervical squamous cancer compared with normal tissues (*P*\<0.01).\
**Abbreviations:** CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; GEPIA, Gene Expression Profiling Interactive Analysis; TPM, transcripts per million.](cmar-10-3533Fig3){#f3-cmar-10-3533}

![RRM2 validation using GSE63514 and PPI network.\
**Notes:** (**A**) GSE63514 showed higher expression of *RRM2* in CC tissues compared with normal cervical tissues (P\<0.01). (**B**) RRM2 PPI network based on STRING.\
**Abbreviations:** CC, cervical cancer; PPI, protein--protein interaction.](cmar-10-3533Fig4){#f4-cmar-10-3533}

###### 

Pathway enrichment analysis of DEGs function in CC

  ID              Description                                                Adjusted *P*-value   Count   Gene symbol
  --------------- ---------------------------------------------------------- -------------------- ------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated                                                                                             
  hsa04110        Cell cycle                                                 2.02E−19             21      *BUB1B*, *CCNB1*, *CCNB2*, *CCNE2*, *CDC7*, *CDK1*, *CDKN2A*, *CDKN2C*, *E2F3*, *MAD2L1*, *MCM2*, *MCM3*, *MCM4*, *MCM5*, *MCM6*, *MCM7*, *ORC6*, *PCNA*, *PTTG1*, *SMC1A*, *TTK*
  hsa03030        DNA replication                                            3.59E−11             10      *FEN1*, *MCM2*, *MCM3*, *MCM4*, *MCM5*, *MCM6*, *MCM7*, *PCNA*, *RFC4*, *RFC5*
  hsa04114        Oocyte meiosis                                             7.63E−04             8       *AURKA*, *CCNB1*, *CCNB2*, *CCNE2*, *CDK1*, *MAD2L1*, *PTTG1*, *SMC1A*
  hsa04115        p53 signaling pathway                                      1.16E−03             6       *CCNB1*, *CCNB2*, *CCNE2*, *CDK1*, *CDKN2A*, *RRM2*
  hsa05206        MicroRNAs in cancer                                        1.07E−02             10      *CCNE2*, *CDKN2A*, *DDIT4*, *DNMT1*, *E2F3*, *EZH2*, *MIR106B*, *MIR25*, *PLAU*, *STMN1*
  hsa04218        Cellular senescence                                        1.44E−02             7       *CCNB1*, *CCNB2*, *CCNE2*, *CDK1*, *CDKN2A*, *CXCL8*, *E2F3*
  hsa03430        Mismatch repair                                            2.09E−02             3       *PCNA*, *RFC4*, *RFC5*
  hsa04914        Progesterone-mediated oocyte maturation                    3.43E−02             5       *AURKA*, *CCNB1*, *CCNB2*, *CDK1*, *MAD2L1*
  hsa05166        HTLV-I infection                                           3.43E--02            8       *BUB1B*, *CCNB2*, *CDKN2A*, *CDKN2C*, *E2F3*, *MAD2L1*, *PCNA*, *PTTG1*
  hsa03410        Base excision repair                                       4.22E−02             3       *FEN1*, *MBD4*, *PCNA*
  Downregulated                                                                                           
  hsa00590        Arachidonic acid metabolism                                2.61E−02             5       *ALOX12*, *ALOX12B*, *ALOX15B*, *GPX3*, *PTGDS*
  hsa04726        Serotonergic synapse                                       2.79E−02             6       *ALOX12*, *ALOX12B*, *ALOX15B*, *CYP2C18*, *DUSP1*, *ITPR2*
  hsa04540        Gap junction                                               3.37E−02             5       *GJA1*, *ITPR2*, *PDGFD*, *TUBA1A*, *TUBB2A*
  hsa04915        Estrogen signaling pathway                                 3.37E−02             6       *CALML3*, *ESR1*, *FOS*, *ITPR2*, *KRT10*, *KRT13*
  hsa04550        Signaling pathways regulating pluripotency of stem cells   3.37E−02             6       *FGFR2*, *FZD1*, *ID4*, *IGF1*, *ISL1*, *KLF4*
  hsa05205        Proteoglycans in cancer                                    3.70E−02             7       *CCND1*, *DCN*, *ESR1*, *FZD1*, *IGF1*, *ITPR2*, *PDCD4*

**Abbreviations:** CC, cervical cancer; DEGs, differentially expressed genes; HTLV-I, human T-lymphotropic virus type 1.

###### 

Results of CMap analysis

  Rank   CMap name          Mean     N     Enrichment   *P*-value
  ------ ------------------ -------- ----- ------------ -----------
  1      Trichostatin A     −0.480   182   −0.419       0
  2      Tanespimycin       −0.372   62    −0.301       0.00002
  3      Vorinostat         −0.551   12    −0.571       0.00034
  4      Trifluoperazine    −0.511   16    −0.488       0.00054
  5      Prochlorperazine   −0.461   16    −0.436       0.00277
  6      Thioridazine       −0.407   20    −0.375       0.00526
  7      Alpha-estradiol    −0.367   16    −0.365       0.02104
  8      Fluphenazine       −0.403   18    −0.326       0.03608
  9      Chlorpromazine     −0.366   19    −0.310       0.04109

**Abbreviation:** CMap, Connectivity Map.
